WEBULL
News
SHIEF
0.128
NaN%
--
Shield Therapeutics Strengthens Financial Position with Amended Debt Financing
TipRanks · 2d ago
Shield Therapeutics Amends Senior Secured Debt Financing with Improved Terms
Reuters · 2d ago
Weekly Report: what happened at SHIEF last week (0908-0912)?
Weekly Report · 09/15 10:45
Weekly Report: what happened at SHIEF last week (0901-0905)?
Weekly Report · 09/08 10:47
Weekly Report: what happened at SHIEF last week (0825-0829)?
Weekly Report · 09/01 10:43
Weekly Report: what happened at SHIEF last week (0818-0822)?
Weekly Report · 08/25 10:52
Weekly Report: what happened at SHIEF last week (0811-0815)?
Weekly Report · 08/18 10:46
Weekly Report: what happened at SHIEF last week (0804-0808)?
Weekly Report · 08/11 10:51
Weekly Report: what happened at SHIEF last week (0728-0801)?
Weekly Report · 08/04 10:54
Weekly Report: what happened at SHIEF last week (0721-0725)?
Weekly Report · 07/28 10:55
Weekly Report: what happened at SHIEF last week (0714-0718)?
Weekly Report · 07/21 10:46
Weekly Report: what happened at SHIEF last week (0707-0711)?
Weekly Report · 07/14 10:54
Weekly Report: what happened at SHIEF last week (0630-0704)?
Weekly Report · 07/07 10:47
Weekly Report: what happened at SHIEF last week (0623-0627)?
Weekly Report · 06/30 10:52
Weekly Report: what happened at SHIEF last week (0616-0620)?
Weekly Report · 06/23 10:46
Weekly Report: what happened at SHIEF last week (0609-0613)?
Weekly Report · 06/16 10:52
Weekly Report: what happened at SHIEF last week (0602-0606)?
Weekly Report · 06/09 10:53
Weekly Report: what happened at SHIEF last week (0526-0530)?
Weekly Report · 06/02 10:59
Weekly Report: what happened at SHIEF last week (0519-0523)?
Weekly Report · 05/26 10:59
Weekly Report: what happened at SHIEF last week (0512-0516)?
Weekly Report · 05/19 10:51
More
Webull provides a variety of real-time SHIEF stock news. You can receive the latest news about Shield Therapeut through multiple platforms. This information may help you make smarter investment decisions.
About SHIEF
Shield Therapeutics plc is a United Kingdom-based commercial-stage pharmaceutical company. The Company delivers differentiated specialty pharmaceuticals that address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company’s lead product, Accrufer/Feraccru, is broadly indicated for use in adults across multiple therapeutic categories. Ferric maltol is approved in the United States, European Union, the United Kingdom, Canada, Australia and Switzerland for the treatment of iron deficiency with or without anemia in adults. It also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialization of ACCRUFeR/FeRACCRU in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. for the Republic of Korea. The Company's subsidiaries include Phosphate Therapeutics Limited, Shield TX (Switzerland) AG, Shield Therapeutics Inc, and Shield TX (UK) Limited.